The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.
Identifieur interne : 000825 ( Main/Corpus ); précédent : 000824; suivant : 000826The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.
Auteurs : Anahid JewettSource :
- Frontiers in immunology [ 1664-3224 ]
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Animals (MeSH), Betacoronavirus (immunology), CD8-Positive T-Lymphocytes (immunology), Coronavirus Infections (blood), Coronavirus Infections (immunology), Coronavirus Infections (therapy), Coronavirus Infections (virology), Cytokines (blood), Disease Progression (MeSH), Female (MeSH), Humans (MeSH), Immunotherapy (methods), Killer Cells, Natural (immunology), Killer Cells, Natural (metabolism), Male (MeSH), Middle Aged (MeSH), Middle East Respiratory Syndrome Coronavirus (immunology), NK Cell Lectin-Like Receptor Subfamily C (metabolism), Neutrophils (immunology), Pandemics (MeSH), Pneumonia, Viral (blood), Pneumonia, Viral (immunology), Pneumonia, Viral (therapy), Pneumonia, Viral (virology).
- MESH :
- chemical , blood : Cytokines.
- blood : Coronavirus Infections, Pneumonia, Viral.
- immunology : Betacoronavirus, CD8-Positive T-Lymphocytes, Coronavirus Infections, Killer Cells, Natural, Middle East Respiratory Syndrome Coronavirus, Neutrophils, Pneumonia, Viral.
- metabolism : Killer Cells, Natural, NK Cell Lectin-Like Receptor Subfamily C.
- methods : Immunotherapy.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Adult, Aged, Animals, Disease Progression, Female, Humans, Male, Middle Aged, Pandemics.
Abstract
Coronavirus-induced disease-2019 (COVID-19) continues to cause significant morbidity and mortality worldwide. While studies on SARS-CoV-2 effects on immune cell function continue to progress, we know very little about the significance of depletion of key immune effectors by the virus in the mortality and morbidity of the disease. This commentary outlines what is the reported literature thus far on the effect of virus on NK cells known to kill virally infected cells. It also underscores the necessity for the future comprehensive studies of NK cells in SARS-CoV-2 infected individuals and animal models to better understand the role and significance of reported NK cell depletion and functional inactivation in disease morbidity and mortality, in hope to design effective therapeutic interventions for the disease.
DOI: 10.3389/fimmu.2020.01692
PubMed: 32754162
PubMed Central: PMC7365845
Links to Exploration step
pubmed:32754162Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.</title><author><name sortKey="Jewett, Anahid" sort="Jewett, Anahid" uniqKey="Jewett A" first="Anahid" last="Jewett">Anahid Jewett</name><affiliation><nlm:affiliation>Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA, Los Angeles, CA, United States.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>The Jonsson Comprehensive Cancer Center, UCLA School of Dentistry and Medicine, Los Angeles, CA, United States.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32754162</idno><idno type="pmid">32754162</idno><idno type="doi">10.3389/fimmu.2020.01692</idno><idno type="pmc">PMC7365845</idno><idno type="wicri:Area/Main/Corpus">000825</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000825</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.</title><author><name sortKey="Jewett, Anahid" sort="Jewett, Anahid" uniqKey="Jewett A" first="Anahid" last="Jewett">Anahid Jewett</name><affiliation><nlm:affiliation>Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA, Los Angeles, CA, United States.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>The Jonsson Comprehensive Cancer Center, UCLA School of Dentistry and Medicine, Los Angeles, CA, United States.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Frontiers in immunology</title><idno type="eISSN">1664-3224</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Animals (MeSH)</term><term>Betacoronavirus (immunology)</term><term>CD8-Positive T-Lymphocytes (immunology)</term><term>Coronavirus Infections (blood)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (therapy)</term><term>Coronavirus Infections (virology)</term><term>Cytokines (blood)</term><term>Disease Progression (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Immunotherapy (methods)</term><term>Killer Cells, Natural (immunology)</term><term>Killer Cells, Natural (metabolism)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Middle East Respiratory Syndrome Coronavirus (immunology)</term><term>NK Cell Lectin-Like Receptor Subfamily C (metabolism)</term><term>Neutrophils (immunology)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (blood)</term><term>Pneumonia, Viral (immunology)</term><term>Pneumonia, Viral (therapy)</term><term>Pneumonia, Viral (virology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term><term>CD8-Positive T-Lymphocytes</term><term>Coronavirus Infections</term><term>Killer Cells, Natural</term><term>Middle East Respiratory Syndrome Coronavirus</term><term>Neutrophils</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Killer Cells, Natural</term><term>NK Cell Lectin-Like Receptor Subfamily C</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunotherapy</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Animals</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus-induced disease-2019 (COVID-19) continues to cause significant morbidity and mortality worldwide. While studies on SARS-CoV-2 effects on immune cell function continue to progress, we know very little about the significance of depletion of key immune effectors by the virus in the mortality and morbidity of the disease. This commentary outlines what is the reported literature thus far on the effect of virus on NK cells known to kill virally infected cells. It also underscores the necessity for the future comprehensive studies of NK cells in SARS-CoV-2 infected individuals and animal models to better understand the role and significance of reported NK cell depletion and functional inactivation in disease morbidity and mortality, in hope to design effective therapeutic interventions for the disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32754162</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><MedlineDate>2020</MedlineDate></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.</ArticleTitle><Pagination><MedlinePgn>1692</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2020.01692</ELocationID><Abstract><AbstractText>Coronavirus-induced disease-2019 (COVID-19) continues to cause significant morbidity and mortality worldwide. While studies on SARS-CoV-2 effects on immune cell function continue to progress, we know very little about the significance of depletion of key immune effectors by the virus in the mortality and morbidity of the disease. This commentary outlines what is the reported literature thus far on the effect of virus on NK cells known to kill virally infected cells. It also underscores the necessity for the future comprehensive studies of NK cells in SARS-CoV-2 infected individuals and animal models to better understand the role and significance of reported NK cell depletion and functional inactivation in disease morbidity and mortality, in hope to design effective therapeutic interventions for the disease.</AbstractText><CopyrightInformation>Copyright © 2020 Jewett.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jewett</LastName><ForeName>Anahid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA, Los Angeles, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Jonsson Comprehensive Cancer Center, UCLA School of Dentistry and Medicine, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C527054">KLRC1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055654">NK Cell Lectin-Like Receptor Subfamily C</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055654" MajorTopicYN="N">NK Cell Lectin-Like Receptor Subfamily C</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">NK cells</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immune cell</Keyword><Keyword MajorTopicYN="N">virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32754162</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.01692</ArticleId><ArticleId IdType="pmc">PMC7365845</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2020 Feb 22;395(10224):565-574</Citation><ArticleIdList><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2018 Jun 21;9:1229</Citation><ArticleIdList><ArticleId IdType="pubmed">29977235</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):762-768</Citation><ArticleIdList><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Ther Oncolytics. 2019 Nov 29;16:41-52</Citation><ArticleIdList><ArticleId IdType="pubmed">31930165</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2020 May 1;368(6490):473-474</Citation><ArticleIdList><ArticleId IdType="pubmed">32303591</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancers (Basel). 2019 Dec 24;12(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">31878338</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Cancer Biol. 2018 Dec;53:178-188</Citation><ArticleIdList><ArticleId IdType="pubmed">30081230</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Immunol. 2001 Nov;22(11):633-40</Citation><ArticleIdList><ArticleId IdType="pubmed">11698225</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2017 Nov 21;47(5):820-833</Citation><ArticleIdList><ArticleId IdType="pubmed">29166586</ArticleId></ArticleIdList></Reference><Reference><Citation>Autoimmun Rev. 2020 Jun;19(6):102537</Citation><ArticleIdList><ArticleId IdType="pubmed">32251717</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2012 Nov 29;3:347</Citation><ArticleIdList><ArticleId IdType="pubmed">23230434</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2000 Nov 25;356(9244):1795-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11117911</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2020 Apr 7;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32265513</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Cell Pathol (Amst). 2018 Aug 2;2018:7871814</Citation><ArticleIdList><ArticleId IdType="pubmed">30175033</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncoimmunology. 2016 Apr 29;5(7):e1178421</Citation><ArticleIdList><ArticleId IdType="pubmed">27622032</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2020 May 11;221(11):1762-1769</Citation><ArticleIdList><ArticleId IdType="pubmed">32227123</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Immunol. 2018 Apr;51:170-180</Citation><ArticleIdList><ArticleId IdType="pubmed">29653339</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2018 Aug 13;9:1869</Citation><ArticleIdList><ArticleId IdType="pubmed">30150991</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 22;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncoimmunology. 2018 Feb 22;7(5):e1426518</Citation><ArticleIdList><ArticleId IdType="pubmed">29721395</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 1999 Feb;5(2):329-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10037182</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Jul;92(7):719-725</Citation><ArticleIdList><ArticleId IdType="pubmed">32170865</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Pathol. 2004 Apr;121(4):507-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15080302</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian Pac J Allergy Immunol. 2020 Mar;38(1):10-18</Citation><ArticleIdList><ArticleId IdType="pubmed">32134278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ageing Res Rev. 2013 Sep;12(4):1069-78</Citation><ArticleIdList><ArticleId IdType="pubmed">23660515</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ Res. 2014 Feb 14;114(4):637-49</Citation><ArticleIdList><ArticleId IdType="pubmed">24366170</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Immunol. 2018 Apr;51:vii-ix</Citation><ArticleIdList><ArticleId IdType="pubmed">29739546</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2020 Jun;26(6):1341-1343</Citation><ArticleIdList><ArticleId IdType="pubmed">32191173</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 27;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32219428</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Feb 24;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Immunol. 2017 Jun;31:37-54</Citation><ArticleIdList><ArticleId IdType="pubmed">28838796</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 Mar;92:214-217</Citation><ArticleIdList><ArticleId IdType="pubmed">32007643</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2020 May;17(5):533-535</Citation><ArticleIdList><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 1996 Jan;2(1):161-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9816103</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biol Sci. 2020 Mar 15;16(10):1753-1766</Citation><ArticleIdList><ArticleId IdType="pubmed">32226295</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Cardiol. 2020 Mar 27;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32219362</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">32105090</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 May;94:29-31</Citation><ArticleIdList><ArticleId IdType="pubmed">32171951</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2017 Apr 05;8:297</Citation><ArticleIdList><ArticleId IdType="pubmed">28424683</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Cell Biol. 2011 Feb;89(2):216-24</Citation><ArticleIdList><ArticleId IdType="pubmed">20567250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000825 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000825 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32754162
|texte= The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32754162" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |